This invention relates to compounds which are generally prostaglandins I2 (IP) receptor modulators, particularly IP receptor antagonists, and which are represented by the general formula (I) wherein A, R and R are defined in the specification; and individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, a process for the preparation of such compounds and their use for treating diseases associated with pain, inflammation, urinary tract disease states, respiratory disease states, edema formation, or hypotensive vascular diseases.